As filed with the Securities and Exchange Commission on March 16, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Aerpio Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 61-1547850 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification Number) | |
Aerpio Pharmaceuticals, Inc. 9987 Carver Road, Suite 420 Cincinnati, OH |
45242 | |
(Address of Principal Executive Offices) | (Zip Code) |
2017 Stock Option and Incentive Plan
Amended and Restated 2017 Employee Stock Purchase Plan
(Full Title of the Plan)
Joseph Gardner
President
Aerpio Pharmaceuticals, Inc.
9987 Carver Road, Suite 420
Cincinnati, OH 45242
(Name and Address of Agent for Service)
(513) 985-1920
(Telephone Number, Including Area Code, of Agent For Service)
Copies to:
Kingsley L. Taft, Esq.
Danielle M. Lauzon, Esq.
James Xu, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Securities To Be Registered |
Amount To Be Registered (1) |
Proposed Maximum Offering Price Per Share |
Proposed Maximum Aggregate Offering Price |
Amount of Registration Fee (6) | ||||
Common Stock, par value $0.0001 per share |
1,623,520 shares(2) | $0.60(3) | $974,112 | $126.44 | ||||
Common Stock, par value $0.0001 per share |
350,000 shares(4) | $0.51(5) | $178,500 | $23.17 | ||||
Total |
1,973,520 shares | $1,152,612 | $149.61 | |||||
| ||||||||
|
(1) | In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall be deemed to cover any additional shares of Common Stock that may become issuable under the Registrants 2017 Stock Option and Incentive Plan (the 2017 Plan) and Amended and Restated 2017 Employee Stock Purchase Plan (the 2017 ESPP) resulting from stock splits, stock dividends, recapitalizations or similar transactions effected without the receipt of consideration which results in an increase in the number of the Registrants outstanding shares of Common Stock. |
(2) | Represents an automatic increase of 1,623,520 shares of the Registrants Common Stock to the number of shares available for issuance under the 2017 Plan, effective January 1, 2020. Shares available for issuance under the 2017 Plan were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission on August 18, 2017 (Registration No. 333-220057), on April 6, 2018 (Registration No. 333-224189) and on March 7, 2019 (Registration No. 333-230114). |
(3) | The price of $0.60 per share, which is the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Capital Market on March 10, 2020, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and has been used as these shares are without a fixed price. |
(4) | Represents an automatic increase of 350,000 shares of the Registrants Common Stock to the number of shares available for issuance under the 2017 ESPP, effective January 1, 2020. Shares available for issuance under the 2017 ESPP were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission on August 18, 2017 (Registration No. 333-220057) and on March 7, 2019 (Registration No. 333-230114). |
(5) | The price of $0.51 per share, which is 85% of the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Capital Market on March 10, 2020, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and has been used as these shares are without a fixed price. Pursuant to the 2017 Employee Stock Purchase Plan, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the fair market value of a share of Common Stock on the first trading day of the offering period or on the exercise date, whichever is less. |
(6) | Calculated pursuant to Section 6(b) of the Securities Act. |
EXPLANATORY NOTE
This Registration Statement on Form S-8 relating to the 2017 Plan and the 2017 ESPP of Aerpio Pharmaceuticals, Inc. (the Registrant) registers additional securities of the same class as other securities for which the Registrants registration statement filed on Form S-8 (Registration No. 333-220057) on August 18, 2017 on Form S-8 (Registration No. 333-224189) on April 6, 2018 and on Form S-8 (Registration No. 333-230114) on March 7, 2019, are effective. Accordingly, the information contained in the Registrants Registration Statement on Form S-8 (SEC File No. 333-220057) is hereby incorporated by reference pursuant to General Instruction E, except for Item 8. Exhibits with respect to which the Exhibit Index is incorporated herein by reference.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cincinnati, State of Ohio, on March 16, 2020.
AERPIO PHARMACEUTICALS, INC. | ||
By: | /s/ Joseph Gardner, Ph.D. | |
Joseph Gardner, Ph.D. President and Principal Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Aerpio Pharmaceuticals, Inc. (the Company), hereby severally constitute and appoint Joseph Gardner and Regina Marek, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments (including post-effective amendments) to this Registration Statement, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, and generally to do all things in our names and on our behalf in such capacities to enable the Company to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
Signature | Title(s) | Date | ||
/s/ Joseph Gardner, Ph.D. Joseph Gardner, Ph.D. |
President, Founder and Director (Principal Executive Officer) | March 16, 2020 | ||
/s/ Regina Marek Regina Marek |
Vice President, Finance (Principal Financial and Accounting Officer) |
March 16, 2020 | ||
/s/ Muneer A. Satter Muneer A. Satter |
Chairman of the Board of Directors | March 16, 2020 | ||
/s/ Chau Khuong Chau Khuong |
Director | March 16, 2020 | ||
/s/ Cheryl Cohen Cheryl Cohen |
Director | March 16, 2020 | ||
/s/ Anupam Dalal, M.D. Anupam Dalal, M.D. |
Director | March 16, 2020 | ||
/s/ Caley Castelein, M.D. Caley Castelein, M.D. |
Director | March 16, 2020 | ||
/s/ Pravin Dugel, M.D. Pravin Dugel, M.D. |
Director | March 16, 2020 | ||
/s/ Steven Prelack Steven Prelack |
Director | March 16, 2020 |
Exhibit 5.1
Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 |
March 16, 2020
Aerpio Pharmaceuticals, Inc.
9987 Carver Road, Suite 420
Cincinnati, OH 45242
Re: | Securities Being Registered under Registration Statement on Form S-8 |
We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (as amended or supplemented, the Registration Statement) pursuant to the Securities Act of 1933, as amended (the Securities Act), on or about the date hereof relating to an aggregate of 1,973,520 shares (the Shares) of Common Stock, $0.0001 par value per share (Common Stock), of Aerpio Pharmaceuticals, Inc., a Delaware corporation (the Company), that may be issued pursuant to the Companys 2017 Stock Option and Incentive Plan and Amended and Restated 2017 Employee Stock Purchase Plan (collectively, the Plans).
We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.
The opinion set forth below is limited to the Delaware General Corporation Law.
For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.
Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.
We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.
Very truly yours, |
/s/ Goodwin Procter LLP
|
GOODWIN PROCTER LLP |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Aerpio Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan, and Aerpio Pharmaceuticals, Inc. Amended and Restated 2017 Employee Stock Purchase Plan, of our report dated March 16, 2020, with respect to the consolidated financial statements of Aerpio Pharmaceuticals, Inc., included in the Annual Report (Form 10-K) for the year ended December 31, 2019, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP |
Cincinnati, Ohio March 16, 2020 |